Profil
Joseph Bishop is an Independent Director at Arbutus Biopharma Corp.
since 2025.
Mr. Bishop is Senior Vice President-Finance at Roivant Social Ventures, Inc. since 2024.
Formerly, Mr. Bishop was a Portfolio Manager at Intrepid Capital Management, Inc. (Connecticut) from 2001 to 2010.
Mr. Bishop was a Portfolio Manager at Citadel Enterprise Americas LLC from 2010 to 2012.
Mr. Bishop was Portfolio Manager & Head-Equities at Pine River Capital Management LLC from 2013 to 2017.
Mr. Bishop completed undergraduate education at the Massachusetts Institute of Technology.
Aktive Positionen von Joseph Bishop
| Unternehmen | Position | Beginn |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 24.02.2025 |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Finanzdirektor/CFO | - |
Ehemalige bekannte Positionen von Joseph Bishop
| Unternehmen | Position | Ende |
|---|---|---|
Pine River Capital Management LLC
Pine River Capital Management LLC Investment ManagersFinance Provides asset management and investment services | Corporate Officer/Principal | 01.01.2017 |
Citadel Enterprise Americas LLC
Citadel Enterprise Americas LLC Investment ManagersFinance Citadel Enterprise invests in public equity, fixed income and alternative investment markets across the globe. The firm seeks to identify the highest and best uses of capital to generate superior long-term returns for their clients. | Corporate Officer/Principal | 01.01.2012 |
Intrepid Capital Management, Inc. (Connecticut)
Intrepid Capital Management, Inc. (Connecticut) Investment ManagersFinance Intrepid Capital Management is a value manager that employs a conservative, contrarian investment strategy. The firm invests long/short in global equities without regard to market-cap. They invest in derivatives including options, warrants, convertibles and index options and employ leverage to hedge their portfolios. Intrepid uses fundamental research to identify stocks with reasonable valuations that are misunderstood by the market, focusing on cash flow and price-to-sales ratios. The firm may occasionally invest in private equity opportunities. | Corporate Officer/Principal | 01.01.2010 |
Ausbildung von Joseph Bishop
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Intrepid Capital Management, Inc. (Connecticut)
Intrepid Capital Management, Inc. (Connecticut) Investment ManagersFinance Intrepid Capital Management is a value manager that employs a conservative, contrarian investment strategy. The firm invests long/short in global equities without regard to market-cap. They invest in derivatives including options, warrants, convertibles and index options and employ leverage to hedge their portfolios. Intrepid uses fundamental research to identify stocks with reasonable valuations that are misunderstood by the market, focusing on cash flow and price-to-sales ratios. The firm may occasionally invest in private equity opportunities. | Finance |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Citadel Enterprise Americas LLC
Citadel Enterprise Americas LLC Investment ManagersFinance Citadel Enterprise invests in public equity, fixed income and alternative investment markets across the globe. The firm seeks to identify the highest and best uses of capital to generate superior long-term returns for their clients. | Finance |
Pine River Capital Management LLC
Pine River Capital Management LLC Investment ManagersFinance Provides asset management and investment services | Finance |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. |
















